| 2020 | Clinical experience of tabelecleucel in patients with EBV plus primary (PID) or acquired immunodeficiency (AID) associated lymphoproliferative disease | Nikiforow, S.; Baiocchi, R.; Nasta, S.; Weng, W.; Loeb, D.; Mahadeo, K. M.; Whangbo, J.; Phuong, P.; Navarro, W.; Gamelin, L.; Sun, Y.; Guzman-Becerra, N.; Prockop, S. | Annals of Oncology | | | |
| 2020 | Long-Term Outcomes of Patients with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Solid Organ Transplant or Allogeneic Hematopoietic Cell Transplant Treated with Tabelecleucel in a Multicenter Expanded Access Program Study | Prockop, S. E.; Reshef, R.; Tsai, D. E.; Bunin, N.; Abu-Arja, R.; Mahadeo, K. M.; Wen-Kai Weng ; van Besien, K.; Loeb, D.; Nasta, S. D.; Nemecek, E. R.; Hiremath, M.; Yue, S.; Sun, Y.; Navarro, W. H.; Nikiforow, S. | Biology of Blood and Marrow Transplantation | | | |
